Loading patent…
AssigneePfizer Inc.
InventorsChristopher Ryan BUTLER, Michelle Renee GARNSEY, Kevin Alexander OGILVIE, Jana POLIVKOVA, Matthew Forrest SAMMONS, Aaron Christopher SMITH, Qingyi Yang
Estimating the term…
Described herein is a crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one having a powder X-ray diffraction pattern comprising at least one characteristic peak, in terms of 2θ at a copper wavelength, selected from 8.7±0.2, 11.1±0.2, and 13.3±0.2.
A crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one having a powder X-ray diffraction pattern comprising at least one characteristic peak, in terms of 2θ at a copper wavelength, wherein the characteristic peak is selected from 8.7±0.2, 11.1±0.2, and 13.3±0.2.
Dependencies are inferred from the claim text.